Brief: Fennec Pharmaceuticals And Norgine Enter Into Exclusive Licensing Agreement To Commercialize Pedmarqsi In Europe, Australia, And New Zealand

Fennec Pharmaceuticals

18/03/2024 01:01

March 17 (Reuters) - Fennec Pharmaceuticals Inc
 FENC.O :
    * FENNEC PHARMACEUTICALS AND NORGINE ENTER INTO EXCLUSIVE
LICENSING AGREEMENT TO COMMERCIALIZE PEDMARQSI IN EUROPE,
AUSTRALIA, AND NEW ZEALAND
    * WILL RECEIVE EUR 40 MILLION IN UPFRONT AND UP TO EUR 210
MILLION
IN ADDITIONAL COMMERCIAL AND REGULATORY MILESTONES,
    * FENNEC - NORGINE WILL BE RESPONSIBLE FOR 
COMMERCIALIZATION
ACTIVITIES IN LICENSED TERRITORIES AND WILL HOLD ALL MARKETING
AUTHORIZATIONS THERE

Source text for Eikon:  ID:nGNXbhg3Gy 
Further company coverage:  FENC.O 

 ((Reuters.Briefs@thomsonreuters.com;))